↓ Skip to main content

NOACs replace VKA as preferred oral anticoagulant among new patients: a drug utilization study in 560 pharmacies in The Netherlands

Overview of attention for article published in Thrombosis Journal, April 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#9 of 172)
  • High Attention Score compared to outputs of the same age (83rd percentile)

Mentioned by

17 tweeters


16 Dimensions

Readers on

32 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
NOACs replace VKA as preferred oral anticoagulant among new patients: a drug utilization study in 560 pharmacies in The Netherlands
Published in
Thrombosis Journal, April 2018
DOI 10.1186/s12959-017-0156-y
Pubmed ID

J. M. van den Heuvel, A. M. Hövels, H. R. Büller, A. K. Mantel-Teeuwisse, A. de Boer, A. H. Maitland-van der Zee


In 2012, around 400.000 patients in the Netherlands were treated with Vitamin K Antagonists (VKA) for thromboembolic diseases. Since 2011, non-VKA oral anticoagulants (NOACs) are available. NOACs do not require frequent INR monitoring which benefits patients, but also imposes a risk of reduced therapy adherence. The objective of this study is to describe uptake and patient adherence of NOACs in The Netherlands until October 2016. Prescription data for 247.927 patients across 560 pharmacies were used to describe patient profiles, uptake of NOACs among new naive patients and switch between VKA and NOACs, and calculate therapy adherence as the Proportion of Days Covered (PDC). During the studied period the share of NOACs in oral anticoagulants has grown to 57% of prescriptions to new patients. More than 70% of new NOAC users were new naive patients and around 26% switched from VKA. The overall share of NOACs among starters is largest in the group of patients of 50-80 years. Calculated compliance rate for NOAC patients shows that 88% of all users are adherent with a PDC higher than 80%. NOAC have overtaken VKA as the major treatment prescribed to new oral anticoagulant patients, and the number of starters on VKA is decreasing. Patients are generally adherent to NOACs during the implementation phase, the period that the medication is used. Fear for inadherence by itself does not need to be a reason for not prescribing NOACs instead of VKA.

Twitter Demographics

The data shown below were collected from the profiles of 17 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 32 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 9 28%
Researcher 3 9%
Professor 3 9%
Student > Bachelor 3 9%
Student > Master 2 6%
Other 6 19%
Unknown 6 19%
Readers by discipline Count As %
Medicine and Dentistry 15 47%
Pharmacology, Toxicology and Pharmaceutical Science 5 16%
Biochemistry, Genetics and Molecular Biology 1 3%
Nursing and Health Professions 1 3%
Immunology and Microbiology 1 3%
Other 1 3%
Unknown 8 25%

Attention Score in Context

This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 September 2018.
All research outputs
of 13,494,757 outputs
Outputs from Thrombosis Journal
of 172 outputs
Outputs of similar age
of 270,915 outputs
Outputs of similar age from Thrombosis Journal
of 1 outputs
Altmetric has tracked 13,494,757 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 172 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.1. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 270,915 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them